Vasopharm taps investors for €20M to fund PhIII trial of brain injury treatment

Nick Paul Taylor

has emerged from talks with armed with €20 million ($ 22 million) to hustle its for traumatic through Phase III. The funding gives vasopharm renewed momentum after a period in which its lead candidate was stuck between trials for several years.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS